Strain Profile
· NCBI Strain Taxon
316435
NCBI Taxonomy's node for this specific strain. A different identifier from the culture-collection deposit numbers below, which name a physical stock rather than a taxonomic node.
How we classify this →
Save
Escherichia coli Nissle 1917
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Escherichia coli Nissle 1917 (EcN) is a non-pathogenic E. coli strain that has been studied for decades as a therapeutic gut colonizer and is notably distinct from disease-causing E. coli strains. Animal model research has examined intestinal barrier integrity and gut microRNA profiles in colitis models, and it has been explored as a vehicle for genetically engineered therapeutic functions, such as heavy-metal sequestration and amino acid metabolism modulation in metabolic disorders. Observational studies have examined the strain's ability to survive transit through the human gut, and reviews have examined its potential relevance to inflammatory bowel disease. Strain-specific evidence for human efficacy in inflammatory conditions is still emerging, and most available mechanistic data come from animal and in vitro experiments. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 1,032 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 443 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+13 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
1483 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
ANIMAL
2026
IN_VITRO
2026
ANIMAL
2026
IN_VITRO
2026
IN_VITRO
2026
ANIMAL
2026
ANIMAL
2026
IN_VITRO
2026
ANIMAL
2026
ANIMAL
2026
REVIEW
2026
ANIMAL
2026
ANIMAL
2026
ANIMAL
2026
IN_VITRO
2026
ANIMAL
2026
ANIMAL
2026
ANIMAL
2026
ANIMAL
2026
ANIMAL
Browse all 1,483 papers →
Raw data for Hansen et al. "Probiotic biogeography and sepsis prevention in the neonatal intestine".
· Figshare
Rapid Phenotypic Screening of Lysine-Degrading Probiotics via FTIR Spectroscopy: Toward Precision Therapy for Hyperlysinemia
· ACS Synthetic Biology
EcN OMV and Alzheimer's disease
· Mendeley Data
Strain-Specific microRNA Reprogramming of Human Dendritic Cells by Probiotic and Commensal Escherichia coli Outer Membrane Vesicles
· Microorganisms
Modulating Innate Immune Responses to Curli Fibers Through Protein Engineering
· bioRxiv (Cold Spring Harbor Laboratory)
In-situ biosynthesis of melanin by genetically engineered probiotics for efficient treatment of acute radiation enteritis
· Nano Research
Dual‐Key Genetic Circuit Enables Stable and Self‐Regulated Engineered Bacteria for the Treatment of Ulcerative Colitis
· Advanced Science
Extracellular Vesicles from Probiotic and Beneficial Escherichia coli Strains Exert Multifaceted Protective Effects Against Rotavirus Infection in Intestinal Epithelial Cells
· Pharmaceutics
A living therapeutic platform for localized in situ modulation of macrophage pyroptosis ameliorates GVHD while preserving GVL
· Journal of Nanobiotechnology
Reprogramming probiotic for uric acid modular degradation and hyperuricemia treatment by synthetic biology regulation
· Microbial Cell Factories
Global Probiotic Markets Meet Synthetic Biology: Translational Challenges and Escherichia coli Nissle 1917 as a Model Chassis
· Microorganisms
Propionate-engineered probiotics reduce radiation-induced intestinal damage
· Bioresources and Bioprocessing
Escherichia coli Nissle 1917 Modulates the RNF150/ELAVL1 Ubiquitination Pathway to Ameliorate Obesity-driven Insulin Resistance in High-fat Diet-fed Mice
· Cellular and Molecular Gastroenterology and Hepatology
A “sticky missile”-like bioactive polyphenol-armored probiotic for targeted immunomodulation and microbiome remodeling in inflammatory bowel disease and its complication
· Advanced Composites and Hybrid Materials
Extracellular Vesicles from Probiotic and Beneficial Escherichia coli Strains Exert Multifaceted Protective Effects Against Rotavirus Infection in Intestinal Epithelial Cells
· Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Surface decoration of bacteria generates robust living therapeutics for improved ulcerative colitis therapy
· Communications Biology
Engineered bacterial therapy suppresses Enterohemorrhagic Escherichia coli through metabolic competition and virulence silencing
· Nature Communications
Cellular membrane protein MipA from E.coli Nissle 1917 protects against Salmonella infection
· The ISME Journal
EcN secreting anti-TNF-alpha nanobody for IBD: 16S rRNA sequencing
· China National GeneBank DataBase
Engineered probiotics for the in vivo mitigation of waterborne uranium toxicity and bioaccumulation
· Environment International
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
PMID 42544624 →The effects of Escherichia coli Nissle 1917 on the gut microbiota composition in ulcerative colitis patients· Minerva Gastroenterology · 2026
-
[2]
PMID 42473331 →Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease· Clinical and Translational Medicine · 2026
-
[3]
PMID 42274393 →Nanoarmored Probiotic for Inflammatory Bowel Disease Bacteriotherapy via a Dual-Targeting Host-Microbiota Reprogramming· ACS Nano · 2026
-
[4]
Source →Escherichia coli Nissle 1917 in Cancer Bacteriotherapy: Functional Applications and Translational Challenges· Russian Journal of Bioorganic Chemistry · 2026
-
[5]
PMID 42725754 →Adhesion‐Enhanced Engineered Probiotic for Prolonged Intestinal Retention and Calprotectin‐Responsive IBD Therapy· Advanced Science · 2026
-
[6]
PMID 41823703 →Cellular membrane protein MipA from E.coli Nissle 1917 protects against Salmonella infection· The ISME Journal · 2026
-
[7]
PMID 42066862 →Bioengineering a Probiotic to Bloom During Colonic Inflammation Promotes Reliable Efficacy in Translational Models of Colitis· Gastroenterology · 2026
-
[8]
PMID 41648437 →Engineered probiotics that sequester arsenite in a mouse gastrointestinal system· bioRxiv (Cold Spring Harbor Laboratory) · 2026
-
[9]
PMID 41813901 →Natural maternal immunity protects neonates from Escherichia coli sepsis· Nature · 2026
-
[10]
Source →Extracellular Vesicles from Probiotic and Beneficial Escherichia coli Strains Exert Multifaceted Protective Effects Against Rotavirus Infection in Intestinal Epithelial Cells· Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · 2026